KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)
Publication
, Journal Article
Siefker-Radtke, AO; Steinberg, G; Bedke, J; Nishiyama, H; Martin, J; Kataria, R; Frenkl, TL; Hoimes, CJ
Published in: Annals of Oncology
October 2019
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
October 2019
Volume
30
Start / End Page
v401 / v401
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Siefker-Radtke, A. O., Steinberg, G., Bedke, J., Nishiyama, H., Martin, J., Kataria, R., … Hoimes, C. J. (2019). KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC). Annals of Oncology, 30, v401–v401. https://doi.org/10.1093/annonc/mdz249.084
Siefker-Radtke, A. O., G. Steinberg, J. Bedke, H. Nishiyama, J. Martin, R. Kataria, T. L. Frenkl, and C. J. Hoimes. “KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC).” Annals of Oncology 30 (October 2019): v401–v401. https://doi.org/10.1093/annonc/mdz249.084.
Siefker-Radtke AO, Steinberg G, Bedke J, Nishiyama H, Martin J, Kataria R, et al. KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC). Annals of Oncology. 2019 Oct;30:v401–v401.
Siefker-Radtke, A. O., et al. “KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC).” Annals of Oncology, vol. 30, Elsevier BV, Oct. 2019, pp. v401–v401. Crossref, doi:10.1093/annonc/mdz249.084.
Siefker-Radtke AO, Steinberg G, Bedke J, Nishiyama H, Martin J, Kataria R, Frenkl TL, Hoimes CJ. KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC). Annals of Oncology. Elsevier BV; 2019 Oct;30:v401–v401.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
October 2019
Volume
30
Start / End Page
v401 / v401
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis